Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Бусад хувилбаруудыг харуулах (1)

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	2008

Ижил төстэй зүйлс

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
-н: Clerico, M, зэрэг
Хэвлэсэн: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
-н: Clerico, M, зэрэг
Хэвлэсэн: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
-н: Clerico, M, зэрэг
Хэвлэсэн: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
-н: Clerico, M, зэрэг
Хэвлэсэн: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
-н: Clerico, M, зэрэг
Хэвлэсэн: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
-н: Valéria Coelho Santa Rita Pereira, зэрэг
Хэвлэсэн: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
-н: Clerico, M, зэрэг
Хэвлэсэн: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
-н: Clerico, M, зэрэг
Хэвлэсэн: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
-н: GJ Melendez-Torres, зэрэг
Хэвлэсэн: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
-н: E.J. Ramos González, зэрэг
Хэвлэсэн: (2021-05-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
-н: Clerico, M, зэрэг
Хэвлэсэн: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
-н: Clerico, M, зэрэг
Хэвлэсэн: (2006)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
-н: N. Y. Lasch
Хэвлэсэн: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
-н: Katarzyna Kapica-Topczewska, зэрэг
Хэвлэсэн: (2019-01-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
-н: G. Ya. Shvarts
Хэвлэсэн: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
-н: Özlem Taşkapılıoğlu, зэрэг
Хэвлэсэн: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
-н: Özlem Taşkapılıoğlu, зэрэг
Хэвлэсэн: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
-н: Oscar Fernández
Хэвлэсэн: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
-н: Massimiliano Mirabella, зэрэг
Хэвлэсэн: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
-н: Mikhail Melnikov, зэрэг
Хэвлэсэн: (2020-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
-н: Methma Udawatta, зэрэг
Хэвлэсэн: (2024-04-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
-н: Aaron Boster, зэрэг
Хэвлэсэн: (2011-09-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
-н: P Tappenden, зэрэг
Хэвлэсэн: (2004-06-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
-н: Anna Gil-Sánchez, зэрэг
Хэвлэсэн: (2024-04-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
-н: Genaro Gabriel Ortíz, зэрэг
Хэвлэсэн: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
-н: Arielle Kasindi, зэрэг
Хэвлэсэн: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
-н: Arthur Komlosh, зэрэг
Хэвлэсэн: (2019-07-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
-н: Ioana S. Barac, зэрэг
Хэвлэсэн: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
-н: T. E. Shmidt
Хэвлэсэн: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
-н: Ignacio Casanova, зэрэг
Хэвлэсэн: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
-н: Justin M. Honce, зэрэг
Хэвлэсэн: (2020-09-01)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
-н: Lyubomira Vlahova, зэрэг
Хэвлэсэн: (2021-02-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
-н: Oliver Neuhaus, зэрэг
Хэвлэсэн: (2021-03-01)

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
-н: María I. Dominguez-Mozo, зэрэг
Хэвлэсэн: (2022-06-01)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
-н: Ümmügülsüm Koc, зэрэг
Хэвлэсэн: (2023-02-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
-н: Fadi Towfic, зэрэг
Хэвлэсэн: (2014-01-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
-н: Oreja-Guevara Celia, зэрэг
Хэвлэсэн: (2012-09-01)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
-н: Apfel Rainer, зэрэг
Хэвлэсэн: (2008-09-01)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
-н: Giannini Marta, зэрэг
Хэвлэсэн: (2012-10-01)

Liver injury and glatiramer acetate, an uncommon association: case report and literature review
-н: Javier Almeida, зэрэг
Хэвлэсэн: (2017-11-01)